Analyzing TrovaGene (NASDAQ:TROV) & Seneca Biopharma (NASDAQ:SNCA)
Seneca Biopharma (NASDAQ:SNCA) and TrovaGene (NASDAQ:TROV) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, profitability, dividends, analyst recommendations, institutional ownership, earnings and risk.
This table compares Seneca Biopharma and TrovaGene’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This table compares Seneca Biopharma and TrovaGene’s top-line revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Seneca Biopharma||$10,000.00||867.38||-$8.35 million||N/A||N/A|
Seneca Biopharma has higher earnings, but lower revenue than TrovaGene.
Insider & Institutional Ownership
6.9% of Seneca Biopharma shares are held by institutional investors. Comparatively, 10.0% of TrovaGene shares are held by institutional investors. 5.4% of Seneca Biopharma shares are held by insiders. Comparatively, 0.6% of TrovaGene shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Risk and Volatility
Seneca Biopharma has a beta of 1.51, meaning that its share price is 51% more volatile than the S&P 500. Comparatively, TrovaGene has a beta of 1.04, meaning that its share price is 4% more volatile than the S&P 500.
This is a summary of current ratings for Seneca Biopharma and TrovaGene, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
TrovaGene has a consensus price target of $5.50, indicating a potential upside of 189.47%. Given TrovaGene’s higher probable upside, analysts plainly believe TrovaGene is more favorable than Seneca Biopharma.
Seneca Biopharma Company Profile
Seneca Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on the research and development of nervous system therapies based on its proprietary human neuronal stem cells and small molecule compounds. The company's stem cell based technology enables the isolation and expansion of human neural stem cells from various areas of the developing human brain and spinal cord enabling the generation of physiologically relevant human neurons of various types. Its lead product candidate is NSI-189, a chemical entity, which has been completed Phase II clinical trial for the treatment of major depressive disorder, as well as is in preclinical study for the treatment-refractory depression, Angelman Syndrome, Alzheimer's disease, ischemic stroke, diabetic neuropathy, irradiation-induced cognitive deficit, and long-term potentiation enhancement. The company also develops NSI-566, which has completed Phase II clinical trial for treating amyotrophic lateral sclerosis disease; Phase II clinical trial for the treatment of chronic ischemic stroke; and Phase I clinical trials for the treatment of chronic spinal cord injury, as well as is in preclinical study for the traumatic brain injury. In addition, it develops NSI-532, which is in preclinical study for treatment of Alzheimer's disease; and NSI-777 that is in preclinical study for treatment of human demyelinating diseases. The company was formerly known as Neuralstem, Inc. and changed its name to Seneca Biopharma, Inc. in October 2019. Seneca Biopharma, Inc. was founded in 1996 and is headquartered in Germantown, Maryland.
TrovaGene Company Profile
Trovagene, Inc., a clinical-stage, precision medicine oncology therapeutics company, develops oncology therapeutics for cancer care by leveraging its proprietary Precision Cancer Monitoring (PCM) technology in tumor genomics. Its lead drug candidate, PCM-075, is a Polo-like Kinase 1 selective adenosine triphosphate competitive inhibitor. The PCM-075 is in Phase Ib/II clinical trial in acute myeloid leukemia (AML) and has completed a Phase I clinical trial in advanced solid tumors. The PCM-075 is also in preclinical studies with approximately 10 chemotherapeutic and target agents used in hematologic and solid tumor cancers, including Zytiga (abiraterone acetate); Beleodaq (belinostat); Quizartinib (AC220), a development stage FLT3 inhibitor; and Velcade (bortezomib) in AML, metastatic castration-resistant prostate cancer and other hematologic and solid tumor cancers. Trovagene, Inc. primarily serves pharmaceutical companies and third party laboratories. The company was formerly known as Xenomics, Inc. and changed its name to Trovagene, Inc. in January 2010. Trovagene, Inc. was founded in 1999 and is headquartered in San Diego, California.
Receive News & Ratings for Seneca Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seneca Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.